Public Employees Retirement Association of Colorado Raises Stake in Edwards Lifesciences Corporation $EW

Public Employees Retirement Association of Colorado raised its position in Edwards Lifesciences Corporation (NYSE:EW) by 1,037.2% in the fourth quarter, Holdings Channel reports. The fund owned 854,314 shares of the medical research company’s stock after buying an additional 779,187 shares during the period. Public Employees Retirement Association of Colorado’s holdings in Edwards Lifesciences were worth $72,830,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in EW. Norges Bank purchased a new position in Edwards Lifesciences in the fourth quarter worth approximately $803,686,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in Edwards Lifesciences by 278.3% in the third quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 5,584,646 shares of the medical research company’s stock worth $434,318,000 after acquiring an additional 4,108,270 shares during the last quarter. Viking Global Investors LP purchased a new position in Edwards Lifesciences in the third quarter worth approximately $238,688,000. Marshall Wace LLP lifted its stake in Edwards Lifesciences by 66.1% in the fourth quarter. Marshall Wace LLP now owns 5,925,627 shares of the medical research company’s stock worth $505,160,000 after acquiring an additional 2,359,128 shares during the last quarter. Finally, AQR Capital Management LLC lifted its stake in Edwards Lifesciences by 114.5% in the third quarter. AQR Capital Management LLC now owns 2,081,346 shares of the medical research company’s stock worth $161,055,000 after acquiring an additional 1,111,139 shares during the last quarter. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on EW shares. Truist Financial set a $90.00 price target on shares of Edwards Lifesciences and gave the stock a “hold” rating in a research note on Friday, April 24th. Wolfe Research raised shares of Edwards Lifesciences from a “peer perform” rating to an “outperform” rating and set a $92.00 price objective on the stock in a report on Wednesday, April 1st. Evercore reissued an “outperform” rating and set a $93.00 price objective on shares of Edwards Lifesciences in a report on Friday, April 24th. Weiss Ratings reissued a “hold (c)” rating on shares of Edwards Lifesciences in a report on Monday, April 20th. Finally, Mizuho set a $95.00 price objective on shares of Edwards Lifesciences and gave the stock an “outperform” rating in a report on Monday, April 13th. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and eight have given a Hold rating to the stock. According to MarketBeat.com, Edwards Lifesciences has an average rating of “Moderate Buy” and a consensus target price of $95.96.

Insider Buying and Selling at Edwards Lifesciences

In other news, VP Donald E. Bobo, Jr. sold 23,145 shares of Edwards Lifesciences stock in a transaction on Wednesday, May 27th. The shares were sold at an average price of $86.42, for a total value of $2,000,190.90. Following the transaction, the vice president directly owned 98,611 shares of the company’s stock, valued at $8,521,962.62. The trade was a 19.01% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, VP Daniel J. Lippis sold 1,019 shares of Edwards Lifesciences stock in a transaction on Friday, May 1st. The shares were sold at an average price of $83.01, for a total transaction of $84,587.19. Following the completion of the transaction, the vice president directly owned 33,934 shares in the company, valued at $2,816,861.34. The trade was a 2.92% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 81,038 shares of company stock valued at $6,683,255. Insiders own 0.31% of the company’s stock.

Edwards Lifesciences Stock Down 0.1%

EW stock opened at $85.02 on Monday. The company has a current ratio of 4.42, a quick ratio of 3.63 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a twelve month low of $72.30 and a twelve month high of $89.48. The company’s 50 day moving average is $82.77 and its two-hundred day moving average is $83.10. The stock has a market cap of $48.95 billion, a P/E ratio of 45.22, a PEG ratio of 2.13 and a beta of 0.87.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Thursday, April 23rd. The medical research company reported $0.78 earnings per share for the quarter, topping analysts’ consensus estimates of $0.73 by $0.05. Edwards Lifesciences had a net margin of 17.39% and a return on equity of 15.19%. The company had revenue of $1.65 billion for the quarter, compared to analysts’ expectations of $1.60 billion. During the same quarter last year, the company earned $0.64 earnings per share. The firm’s revenue for the quarter was up 16.7% on a year-over-year basis. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. Research analysts expect that Edwards Lifesciences Corporation will post 3 earnings per share for the current fiscal year.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.